EUVIMEDEUVIMED entdecken
EditorialOpen Access

Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma

Jacob N Stein iD, Mark G Woodcock iD, Kevin Y Chen iD

JCO Oncology Practice · 12.06.2026

DOI: 10.1200/op-26-00502 ↗

Kurz gefasst

Editorial in der Zeitschrift JCO Oncology Practice, online erschienen am 12.06.2026. Verfasst von Jacob N Stein und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A Brief History of Sarcoma and DoxorubicinSoft tissue sarcomas (STS) are characterized by their rarity, heterogeneity, and poor responsiveness to therapy.Less than 1% of all adult malignancies are sarcomas, comprising

Autor:innen und Institutionen

  • Division of Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Lineberger Comprehensive Cancer Center, Chapel Hill, NC.

ORCID-Profile: Jacob N Stein, Mark G Woodcock, Kevin Y Chen

Förderung

  • NCI NIH HHS

Zitieren

APA

Stein, J. N., Woodcock, M. G., & Chen, K. Y. (2026). Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma. JCO Oncology Practice. https://doi.org/10.1200/op-26-00502

Vancouver

Stein JN, Woodcock MG, Chen KY. Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma. JCO Oncology Practice. 2026. doi:10.1200/op-26-00502

BibTeX
@article{Stein2026,
  author = {Stein, Jacob N and Woodcock, Mark G and Chen, Kevin Y},
  title = {Challenging the Conventional Wisdom Around Doxorubicin in Soft Tissue Sarcoma},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-26-00502}
}
Kostenlos starten →